CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors.

@article{Mamedova2005CysLT1LR,
  title={CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors.},
  author={Liaman K. Mamedova and Val{\'e}rie Capra and Maria Rosa Accomazzo and Z L Gao and Silvia Ferrario and Marta Fumagalli and Maria P. Abbracchio and Gianenrico Rovati and Kenneth A. Jacobson},
  journal={Biochemical pharmacology},
  year={2005},
  volume={71 1-2},
  pages={115-25}
}
Montelukast and pranlukast are orally active leukotriene receptor antagonists selective for the CysLT1 receptor. Conversely, the hP2Y(1,2,4,6,11,12,13,14) receptors represent a large family of GPCRs responding to either adenine or uracil nucleotides, or to sugar-nucleotides. Montelukast and pranlukast were found to inhibit nucleotide-induced calcium mobilization in a human monocyte-macrophage like cell line, DMSO-differentiated U937 (dU937). Montelukast and pranlukast inhibited the effects of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Role of cysteinyl leukotriene signaling in a mouse model of noise-induced cochlear injury.

Proceedings of the National Academy of Sciences of the United States of America • 2014

Similar Papers

Loading similar papers…